BioLife Solutions (BLFS) CFO sells 833 shares at $27.36
BioLife Solutions (BLFS) reported an insider transaction by its Chief Financial Officer.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioLife Solutions (BLFS) reported an insider transaction by its Chief Financial Officer. On 10/09/2025, the CFO executed a sale of 833 shares of common stock at a price of $27.36 per share. Following this transaction, the officer beneficially owns 183,353 shares, held directly.
The filing notes the sale was made pursuant to a Rule 10b5-1(c) trading plan, effective 01/03/2023, to satisfy tax withholding obligations arising from the vesting of restricted stock. This indicates a pre-established, automated plan tied to equity award taxation rather than a discretionary open‑market trade.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 833 | $27.36 | $23K |
Footnotes (1)
- F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did BioLife Solutions (BLFS) disclose in this Form 4?
Who is the reporting person and their role at BLFS?
Was the BLFS insider sale under a 10b5-1 plan?
What was the purpose of the sale according to the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.